Agensys, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1997-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.agensys.com
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Agensys, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT01672775
- Locations
- 🇺🇸
Site US00001 Seattle Cancer Care Alliance, Seattle, Washington, United States
🇨🇦Site CA00006 Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Site CA00007 Jewish General Hospital, Montreal, Quebec, Canada
A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Agensys, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT01608711
- Locations
- 🇺🇸
Site US116, Madison, Wisconsin, United States
🇨🇦Site CA00203, Toronto, Canada
© Copyright 2024. All Rights Reserved by MedPath